Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
14.8M
-
Shares change
-
+319K
-
Total reported value, excl. options
-
$185M
-
Value change
-
+$2M
-
Put/Call ratio
-
0.22
-
Number of buys
-
37
-
Number of sells
-
-46
-
Price
-
$12.52
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q4 2016
123 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2016.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.8M shares
of 207M outstanding shares and own 7.13% of the company stock.
Largest 10 shareholders include Pentwater Capital Management LP (1.83M shares), Aisling Capital LLC (1.64M shares), BB BIOTECH AG (1.31M shares), DISCOVERY CAPITAL MANAGEMENT, LLC / CT (1.04M shares), BlackRock Fund Advisors (789K shares), FMR LLC (766K shares), BVF INC/IL (713K shares), CREDIT SUISSE AG/ (695K shares), VANGUARD GROUP INC (601K shares), and WASATCH ADVISORS INC (538K shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.